Comerica Bank Vertex Pharmaceuticals Inc Transaction History

Comerica Bank

  • $24.4 Billion
  • Q4 2024

A detailed history of Comerica Bank transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Comerica Bank holds 49,578 shares of VRTX stock, worth $24.9 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
49,578
Previous 53,623 7.54%
Holding current value
$24.9 Million
Previous $24.9 Million 19.94%
% of portfolio
0.08%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$396.64 - $516.74 $1.6 Million - $2.09 Million
-4,045 Reduced 7.54%
49,578 $20 Million
Q3 2024

Nov 14, 2024
BUY
$460.0 - $505.78 $410,780 - $451,661
893 Added 1.69%
53,623 $24.9 Million
Q2 2024

Aug 15, 2024
SELL
$392.81 - $485.53 $648,136 - $801,124
-1,650 Reduced 3.03%
52,730 $24.7 Million
Q1 2024

May 15, 2024
SELL
$407.69 - $446.08 $1.51 Million - $1.65 Million
-3,706 Reduced 6.38%
54,380 $22.7 Million
Q4 2023

Feb 14, 2024
SELL
$343.0 - $410.68 $710,010 - $850,107
-2,070 Reduced 3.44%
58,086 $23.6 Million
Q3 2023

Nov 21, 2023
BUY
$338.18 - $362.46 $14.3 Million - $15.3 Million
42,333 Added 237.52%
60,156 $20.9 Million
Q2 2023

Aug 22, 2023
SELL
$314.42 - $351.91 $6.58 Million - $7.36 Million
-20,913 Reduced 53.99%
17,823 $89,000
Q4 2022

Jan 26, 2023
BUY
$285.76 - $321.48 $911,574 - $1.03 Million
3,190 Added 8.97%
38,736 $0
Q3 2022

Oct 28, 2022
BUY
$273.83 - $305.53 $291,081 - $324,778
1,063 Added 3.08%
35,546 $11 Million
Q2 2022

Aug 02, 2022
SELL
$234.96 - $292.55 $31,954 - $39,786
-136 Reduced 0.39%
34,483 $9.99 Million
Q1 2022

Apr 27, 2022
BUY
$221.42 - $260.97 $65,097 - $76,725
294 Added 0.86%
34,619 $9.03 Million
Q4 2021

Feb 18, 2022
SELL
$177.01 - $223.45 $9.28 Million - $11.7 Million
-52,411 Reduced 60.43%
34,325 $7.54 Million
Q3 2021

Nov 22, 2021
BUY
$181.39 - $202.99 $6.88 Million - $7.7 Million
37,937 Added 77.74%
86,736 $15.7 Million
Q2 2021

Aug 26, 2021
SELL
$187.49 - $221.1 $290,984 - $343,147
-1,552 Reduced 3.08%
48,799 $9.84 Million
Q1 2021

Apr 28, 2021
SELL
$207.02 - $241.31 $141,808 - $165,297
-685 Reduced 1.34%
50,351 $10.8 Million
Q4 2020

Jan 28, 2021
SELL
$207.01 - $276.09 $1.07 Million - $1.43 Million
-5,189 Reduced 9.23%
51,036 $12.1 Million
Q3 2020

Oct 30, 2020
BUY
$255.65 - $303.1 $334,645 - $396,757
1,309 Added 2.38%
56,225 $15.3 Million
Q2 2020

Jul 31, 2020
BUY
$225.48 - $295.8 $533,034 - $699,271
2,364 Added 4.5%
54,916 $15.9 Million
Q1 2020

May 01, 2020
SELL
$199.77 - $247.81 $77,510 - $96,150
-388 Reduced 0.73%
52,552 $12.5 Million
Q4 2019

Feb 07, 2020
SELL
$166.71 - $223.91 $544,141 - $730,842
-3,264 Reduced 5.81%
52,940 $11.6 Million
Q3 2019

Oct 31, 2019
BUY
$166.23 - $187.09 $93,088 - $104,770
560 Added 1.01%
56,204 $9.52 Million
Q2 2019

Aug 02, 2019
BUY
$164.61 - $190.37 $174,980 - $202,363
1,063 Added 1.95%
55,644 $0
Q1 2019

May 02, 2019
SELL
$163.73 - $194.7 $31,272 - $37,187
-191 Reduced 0.35%
54,581 $0
Q4 2018

Feb 06, 2019
SELL
$151.91 - $192.21 $53,624 - $67,850
-353 Reduced 0.64%
54,772 $10.2 Million
Q3 2018

Nov 01, 2018
SELL
$167.73 - $192.74 $2.5 Million - $2.87 Million
-14,899 Reduced 21.28%
55,125 $9.6 Million
Q2 2018

Aug 01, 2018
BUY
$145.72 - $169.96 $15,446 - $18,015
106 Added 0.15%
70,024 $12.8 Million
Q1 2018

May 01, 2018
SELL
$151.6 - $177.13 $196,473 - $229,560
-1,296 Reduced 1.82%
69,918 $11.2 Million
Q4 2017

Feb 02, 2018
BUY
$137.28 - $155.55 $1.48 Million - $1.68 Million
10,801 Added 17.88%
71,214 $11.9 Million
Q3 2017

Nov 06, 2017
BUY
$148.13 - $162.24 $8.95 Million - $9.8 Million
60,413
60,413 $9.03 Million

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email